Course Description
According to the 2020 National Survey on Drug Use and Health, an estimated 10.3 million people (3.7%) aged 12 or older misused CNS stimulants (cocaine, methamphetamine, or prescription stimulants) in the past year. There is no FDA approved medication currently available for stimulant use disorders and evidence-based treatment options are limited. There are many studies available evaluating the many options for treatment of stimulant use disorder, but little clinical application has resulted thus far. A review of current pharmacotherapy treatment approaches and outcomes may be beneficial to the pharmacist who does not typically work with patients diagnosed with substance use disorders. In addition to treatment options, there are currently vaccines in development for the treatment of cocaine use disorder and methamphetamine use disorder. The cocaine vaccine, which is designed to absorb cocaine in the bloodstream, was approved for a Phase I and Phase II clinical trials. The methamphetamine vaccine has been approved for Phase I clinical trial.
During treatment of substance use disorders, the focus is often on preventing acute effects of substance misuse. Chronic stimulant use may result in a number of health issues including serious cardiovascular complications such as angina, valvular disease, stroke, and an increases risk for heart attack. Chronic stimulant use can also permanently alter brain structure, leading to impaired cognitive, neurological, and emotional systems. In pregnant mothers, there are also long-term effects of stimulant misuse including risk of neurodevelopmental problems in the fetus. Improved patient education on the long-term consequences of stimulant misuse could prevent these complications.
Learning Objectives
- Explain the prevalence and consequences of stimulant misuse and stimulant use disorders in the United States.
- Evaluate the evidence supporting pharmacotherapies for stimulant use disorders.
- Provide patient education and harm reduction strategies to prevent long-term consequences of stimulant use disorder.
Target Audience
If you are a pharmacist, nurse practitioner or other healthcare professional involved in the comprehensive medication management of psychiatric patients, we invite you to participate in this online course.
Faculty
View biographical information
Phillip Coffin, MD, MIA, VACP, FIDCA
Director of Substance Use Research
San Francisco Department of Public Health
Division of HIV, ID & Global Medicine, University of California, San Francisco
San Francisco, CA
Phillip Coffin MD, MIA is a board-certified and practicing internist, infectious disease specialist, and addiction medicine specialist. He attended or trained at Brown University, Columbia University, the University of California San Francisco, and the University of Washington. He directs the Center on Substance Use and Health at the San Francisco Department of Public Health, including clinical trials assessing medications for multiple substance use disorders and interventions for opioid safety, overdose prevention, HIV prevention, and Hepatitis C treatment. Dr. Phillip Coffin also conducts several studies into the impacts of changing opioid prescribing practices on vulnerable populations, substance use epidemiology, and initiatives addressing substance use and opioid safety in clinical care.
Course Requirements
To receive ACPE credit for this session, you must:
- Register for this course.
- Review the full content of the activity and reflect upon its teachings.
- Complete the evaluation at the end of the activity.
- Provide the necessary details in your profile to ensure correct reporting by AAPP to CPE Monitor.
Continuing Education Credit and Disclosures
Activity Date: 10/07/2022
ACPE Contact Hours: 1.25
ACPE Number: 0284-0000-22-076-H01-P (Application)
Nursing Credit Reminder: Note that ACPE credit is accepted for ANCC Certification Renewal and AANPCB advanced practice provider content. For specific questions related to your organization's acceptance of ACPE continuing education units, please contact your organization directly.
The College of Psychiatric and Neurologic Pharmacists is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.
AAPP owns the copyright, is licensed or has received permissions for use of, or is otherwise permitted to use copyrighted materials within any CPE activity. Authors and speakers are required to obtain necessary copyright permissions for content in CPE activities. AAPP complies with copyright laws and regulations.
View planning committee disclosures
2022 Planning Committee
|
Ericka Crouse, PharmD, BCPP, BCGP, FASHP, FASCP Associate Professor VCU School of Pharmacy Richmond, VA External Consultant Activities, Advisory Panels, Speakers Bureaus, etc.: ASHP - PAM Behavioral Health Committee (volunteer), Editorial Board - The Medical Letter (paid), American Society of Consultant Pharmacists - speak at meetings/webinars on GeroPsych topics (paid), Wolters-Kluwer, paid consultant |
|
Cassandra Davis, PharmD, BCPP, BCPS Mental Health Clinical Pharmacy Specialist Orlando VA Medical Center Orlando, FL No Relevant Financial Relationships to Disclose |
 Megan J. Ehret, PharmD, BCPP, MSBCPP Program Director Professor University of Maryland Baltimore, MD External Consultant Activities, Advisory Panels, Speakers Bureaus, etc.: Psych U Section Advisor, Lexi-Comp Consultant/Reviewer, SMI Adviser; Pharmacist Consultant Educational Grants, Research Grants or Contracts: FDA/University of Maryland CERSI, Maryland Behavioral Health Department, NIH |
 Sarah Melton, PharmD, BCPP, BCACP, FASCPChair Professor of Pharmacy Practice Gatton College of Pharmacy Johnson City, TN Non-Financial Interests: One Care of Southwest Virginia, Virginia Board of Pharmacy, Virginia Opioid Abatement Authority, Overmountain Recovery, Virginia Department of Health Professions Board, Virginia Medicaid Pharmacy and Therapeutics Committee |
|
Troy Moore, PharmD, MS, BCPP |
|
Erika Titus-Lay, PharmD, BCPP, BCPS Assistant Professor California Northstate University College of Pharmacy Elk Grove, CA Educational Grants, Research Grants or Contracts: Sponsor, ASHP Pharmacy Leadership Scholars Research Grant |
2022 Reviewers
|
Audrey Abelleira, PharmD, BCPP, BCPS |
|
David Dadiomov, PharmD, BCPP |
|
James J. Gasper, PharmD, BCPP |
|
Cindy A. Gutierrez, PharmD, MS, BCPP |
|
Dara L. Johnson, PharmD, BCPP, BCACP |
|
Benjamin Miskle, PharmD |
|
Marnie Noel, PharmD, BCPP |
All relevant relationships have been mitigated.
All relevant relationships have been mitigated.
View disclaimer and disclosure of off-label use
Off-Label Use: This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA (see faculty information). The opinions expressed in the educational activity do not necessarily represent the views of AAPP and any educational partners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Disclaimer: Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Presentation-Specific Disclosure: My presentation will include discussion of off-label, experimental, and /or investigational use of drugs or devices: mirtazapine, bupropion, naltrexone, experimental vaccines and immunotherapies, etc
View fair balance and integrity statement
It is the policy of AAPP to ensure independence, balance, objectivity, scientific rigor, and integrity in continuing education activities. Those involved in the development of this continuing education activity have made all reasonable efforts to ensure that information contained herein is accurate in accordance with the latest available scientific knowledge at the time of accreditation of this continuing education activity. Information regarding drugs (e.g., their administration, dosages, contraindications, adverse reactions, interactions, special warnings, and precautions) and drug delivery systems is subject to change, however, and the reader is advised to check the manufacturer’s package insert for information concerning recommended dosage and potential problems or cautions prior to dispensing or administering the drug or using the drug delivery systems.
Fair balance is achieved through ongoing and thorough review of all materials produced by faculty, and all educational and advertising materials produced by supporting organizations, prior to educational offerings. Approval of credit for this continuing education activity does not imply endorsement by AAPP for any product or manufacturer identified.